.
Por que é que o preço dos
medicamentos pode ser secreto?
𝖮 𝖨𝗇𝖿𝖺𝗋𝗆𝖾𝖽 𝖼𝗈𝗆𝗎𝗇𝗂𝖼𝗈𝗎 𝗇𝖺 𝗌𝖾𝗆𝖺𝗇𝖺 𝗉𝖺𝗌𝗌𝖺𝖽𝖺 𝗊𝗎𝖾 𝟥𝟥 𝖼𝗋𝗂𝖺𝗇𝖼̧𝖺𝗌 𝗋𝖾𝖼𝖾𝖻𝖾𝗋𝖺𝗆 𝖾𝗆 𝖯𝗈𝗋𝗍𝗎𝗀𝖺𝗅, 𝖽𝖾𝗌𝖽𝖾 𝟤𝟢𝟣𝟫, 𝗈 𝖹𝗈𝗅𝗀𝖾𝗇𝗌𝗆𝖺, 𝗈 𝗍𝖺𝗅 𝗆𝖾𝖽𝗂𝖼𝖺𝗆𝖾𝗇𝗍𝗈 𝗊𝗎𝖾 𝖼𝗎𝗌𝗍𝖺𝗏𝖺 𝖽𝗈𝗂𝗌 𝗆𝗂𝗅𝗁𝗈̃𝖾𝗌 𝖽𝖾 𝖾𝗎𝗋𝗈𝗌 𝖾𝗆 𝟤 𝖽𝖾 𝗆𝖺𝗋𝖼̧𝗈 𝖽𝖾 𝟤𝟢𝟤𝟢, 𝖽𝖺𝗍𝖺 𝖾𝗆 𝗊𝗎𝖾 𝗈 𝗆𝖾𝗌𝗆𝗈 𝗈𝗋𝗀𝖺𝗇𝗂𝗌𝗆𝗈 𝖺𝗉𝗋𝗈𝗏𝗈𝗎 𝖺 𝗌𝗎𝖺 𝖺𝗉𝗅𝗂𝖼𝖺𝖼̧𝖺̃𝗈 𝖺̀𝗌 𝗀𝖾́𝗆𝖾𝖺𝗌 𝗊𝗎𝖾 𝖾𝗌𝗍𝖺̃𝗈 𝗌𝗈𝖻 𝗌𝗎𝗌𝗉𝖾𝗂𝗍𝖺 𝖽𝖾 𝗍𝖾𝗋𝖾𝗆 𝖻𝖾𝗇𝖾𝖿𝗂𝖼𝗂𝖺𝖽𝗈 𝖽𝖾 𝗎𝗆 𝗍𝗋𝖺𝗍𝖺𝗆𝖾𝗇𝗍𝗈 𝖽𝖾 𝖿𝖺𝗏𝗈𝗋, 𝖺𝗉𝗈́𝗌 𝗎𝗆 𝗉𝖾𝖽𝗂𝖽𝗈 𝖽𝖾 𝗂𝗇𝖿𝗈𝗋𝗆𝖺𝖼̧𝖺̃𝗈 𝖿𝖾𝗂𝗍𝗈 𝖺̀ 𝖯𝗋𝖾𝗌𝗂𝖽𝖾̂𝗇𝖼𝗂𝖺 𝖽𝖺 𝖱𝖾𝗉𝗎́𝖻𝗅𝗂𝖼𝖺, 𝗊𝗎𝖾 𝗅𝖾𝗏𝖺𝗇𝗍𝗈𝗎 𝗎𝗆𝖺 𝗁𝗂𝗉𝗈́𝗍𝖾𝗌𝖾 𝖽𝖾 "𝖼𝗎𝗇𝗁𝖺" 𝗂𝗇𝗌𝗍𝗂𝗍𝗎𝖼𝗂𝗈𝗇𝖺𝗅, 𝗈 𝗊𝗎𝖾 𝖼𝗋𝗂𝗈𝗎 𝗆𝖺𝗂𝗌 𝗎𝗆 𝗆𝗈𝗍𝗂𝗏𝗈 𝖽𝖾 𝖺𝗀𝗂𝗍𝖺𝖼̧𝖺̃𝗈 𝗉𝗈𝗅𝗂́𝗍𝗂𝖼𝖺 𝖾𝗆 𝖯𝗈𝗋𝗍𝗎𝗀𝖺𝗅, 𝖺𝗉𝗈́𝗌 𝗎𝗆𝖺 𝗉𝖾𝗋𝗍𝗂𝗇𝖾𝗇𝗍𝖾 𝗂𝗇𝗏𝖾𝗌𝗍𝗂𝗀𝖺𝖼̧𝖺̃𝗈 𝗃𝗈𝗋𝗇𝖺𝗅𝗂́𝗌𝗍𝗂𝖼𝖺 𝖽𝖺 𝖳𝖵𝖨.
𝖮 𝖽𝗂𝗍𝗈 𝖨𝗇𝖿𝖺𝗋𝗆𝖾𝖽, 𝖺 𝗂𝗇𝗌𝗍𝗂𝗍𝗎𝗂𝖼̧𝖺̃𝗈 𝗊𝗎𝖾 𝖺𝗎𝗍𝗈𝗋𝗂𝗓𝖺 𝖺 𝖼𝗈𝗆𝖾𝗋𝖼𝗂𝖺𝗅𝗂𝗓𝖺𝖼̧𝖺̃𝗈 𝖽𝖾 𝗆𝖾𝖽𝗂𝖼𝖺𝗆𝖾𝗇𝗍𝗈𝗌 𝖾𝗆 𝖯𝗈𝗋𝗍𝗎𝗀𝖺𝗅, 𝖾𝗑𝗉𝗅𝗂𝖼𝗈𝗎 𝖺𝗂𝗇𝖽𝖺 𝗊𝗎𝖾 𝗈 𝖹𝗈𝗅𝗀𝖾𝗇𝗌𝗆𝖺 𝗃𝖺́ 𝗇𝖺̃𝗈 𝖼𝗎𝗌𝗍𝖺 𝖽𝗈𝗂𝗌 𝗆𝗂𝗅𝗁𝗈̃𝖾𝗌 𝖽𝖾 𝖾𝗎𝗋𝗈𝗌, 𝗆𝖺𝗌 𝗋𝖾𝖼𝗎𝗌𝗈𝗎 𝖽𝗂𝗓𝖾𝗋 𝗈 𝗉𝗋𝖾𝖼̧𝗈 𝖺𝗍𝗎𝖺𝗅, 𝖾𝗆𝖻𝗈𝗋𝖺 𝖺𝖽𝗂𝖺𝗇𝗍𝖾 𝗊𝗎𝖾 𝖾́ "𝗌𝗎𝖻𝗌𝗍𝖺𝗇𝖼𝗂𝖺𝗅𝗆𝖾𝗇𝗍𝖾 𝗆𝖺𝗂𝗌 𝖻𝖺𝗂𝗑𝗈". 𝖭𝗎𝗆𝖺 𝗋𝖾𝗌𝗉𝗈𝗌𝗍𝖺 𝖺 𝗎𝗆𝖺 𝗉𝖾𝗋𝗀𝗎𝗇𝗍𝖺 𝖽𝖺 𝖠𝗀𝖾̂𝗇𝖼𝗂𝖺 𝖫𝗎𝗌𝖺, 𝖽𝗂𝗓-𝗌𝖾 𝗊𝗎𝖾 𝗍𝖺𝗅 𝗌𝗂𝗅𝖾̂𝗇𝖼𝗂𝗈 𝗌𝖾 𝖽𝖾𝗏𝖾 "𝖺̀𝗌 𝖼𝗅𝖺́𝗎𝗌𝗎𝗅𝖺𝗌 𝖽𝖾 𝖼𝗈𝗇𝖿𝗂𝖽𝖾𝗇𝖼𝗂𝖺𝗅𝗂𝖽𝖺𝖽𝖾 𝗂𝗇𝖼𝗅𝗎𝗂́𝖽𝖺𝗌 𝗇𝗈𝗌 𝖼𝗈𝗇𝗍𝗋𝖺𝗍𝗈𝗌 𝖽𝖾 𝖿𝗂𝗇𝖺𝗇𝖼𝗂𝖺𝗆𝖾𝗇𝗍𝗈 𝖺 𝗉𝖾𝖽𝗂𝖽𝗈 𝖽𝗈𝗌 𝗅𝖺𝖻𝗈𝗋𝖺𝗍𝗈́𝗋𝗂𝗈𝗌 𝖽𝖾𝗍𝖾𝗇𝗍𝗈𝗋𝖾𝗌 𝖽𝗈𝗌 𝗆𝖾𝖽𝗂𝖼𝖺𝗆𝖾𝗇𝗍𝗈𝗌".
𝖮 𝗋𝖾𝗆𝖾́𝖽𝗂𝗈 𝖾́ 𝖿𝖺𝖻𝗋𝗂𝖼𝖺𝖽𝗈 𝗉𝖾𝗅𝖺 𝖭𝗈𝗏𝖺𝗋𝗍𝗂𝗌, 𝗎𝗆𝖺 𝖾𝗆𝗉𝗋𝖾𝗌𝖺 𝖽𝖾 𝗈𝗋𝗂𝗀𝖾𝗆 𝗌𝗎𝗂́𝖼̧𝖺 𝗊𝗎𝖾 𝖾́ 𝗎𝗆 𝖽𝗈𝗌 𝗀𝗋𝖺𝗇𝖽𝖾𝗌 𝖼𝗈𝗇𝗀𝗅𝗈𝗆𝖾𝗋𝖺𝖽𝗈𝗌 𝗆𝗎𝗇𝖽𝗂𝖺𝗂𝗌 𝖽𝖾𝗌𝗌𝖺 𝗂𝗇𝖽𝗎́𝗌𝗍𝗋𝗂𝖺. 𝖤𝗅𝖺 𝖺𝗅𝖾𝗀𝖺 𝗊𝗎𝖾 𝗂𝗇𝗏𝖾𝗌𝗍𝗂𝗎 "𝖼𝖾𝗇𝗍𝖾𝗇𝖺𝗌 𝖽𝖾 𝗆𝗂𝗅𝗁𝗈̃𝖾𝗌 𝖽𝖾 𝖽𝗈́𝗅𝖺𝗋𝖾𝗌" 𝖾𝗆 𝟣𝟤 𝖺𝗇𝗈𝗌 𝖽𝖾 𝗂𝗇𝗏𝖾𝗌𝗍𝗂𝗀𝖺𝖼̧𝖺̃𝗈 𝖼𝗂𝖾𝗇𝗍𝗂́𝖿𝗂𝖼𝖺 𝗉𝖺𝗋𝖺 𝖼𝗈𝗇𝗌𝖾𝗀𝗎𝗂𝗋 𝗈𝖻𝗍𝖾𝗋 𝖾𝗌𝗍𝖾 𝗍𝗋𝖺𝗍𝖺𝗆𝖾𝗇𝗍𝗈 𝗂𝗇𝗈𝗏𝖺𝖽𝗈𝗋 𝗉𝖺𝗋𝖺 𝖺 𝖺𝗍𝗋𝗈𝖿𝗂𝖺 𝗆𝗎𝗌𝖼𝗎𝗅𝖺𝗋 𝖾𝗌𝗉𝗂𝗇𝖺𝗅.
𝖴𝗆𝖺 𝗇𝗈𝗍𝗂́𝖼𝗂𝖺 𝖽𝗈 𝗃𝗈𝗋𝗇𝖺𝗅 𝖯𝗎́𝖻𝗅𝗂𝖼𝗈 𝖾𝗑𝗉𝗅𝗂𝖼𝖺 𝗊𝗎𝖾 𝖺 𝖭𝗈𝗏𝖺𝗋𝗍𝗂𝗌 𝖼𝗈𝗆𝗉𝗋𝗈𝗎 𝖾𝗆 𝟤𝟢𝟣𝟪 𝗈 𝗅𝖺𝖻𝗈𝗋𝖺𝗍𝗈́𝗋𝗂𝗈 𝖠𝗏𝖾𝗑𝗂𝗌, 𝗊𝗎𝖾 𝗂𝗇𝗏𝖾𝗌𝗍𝗂𝗀𝖺𝗏𝖺 𝗈 𝖿𝖺́𝗋𝗆𝖺𝖼𝗈, 𝗉𝗈𝗋 𝗌𝖾𝗍𝖾 𝗆𝗂𝗅 𝗆𝗂𝗅𝗁𝗈̃𝖾𝗌 𝖽𝖾 𝖾𝗎𝗋𝗈𝗌, 𝖾 𝗊𝗎𝖾 𝗈 𝖹𝗈𝗅𝗀𝖾𝗇𝗌𝗆𝖺 𝗋𝖾𝗇𝖽𝖾𝗎 𝖾𝗇𝗍𝗋𝖾𝗍𝖺𝗇𝗍𝗈 𝟦𝟤𝟦𝟢 𝗆𝗂𝗅𝗁𝗈̃𝖾𝗌 𝖽𝖾 𝖾𝗎𝗋𝗈𝗌, 𝗌𝖾𝗀𝗎𝗇𝖽𝗈 𝗈𝗌 𝗋𝖾𝗅𝖺𝗍𝗈́𝗋𝗂𝗈𝗌 𝖾 𝖼𝗈𝗇𝗍𝖺𝗌 𝖽𝖺 𝖾𝗆𝗉𝗋𝖾𝗌𝖺.
𝖠 𝗂𝗇𝖼𝗂𝖽𝖾̂𝗇𝖼𝗂𝖺 𝖽𝖾𝗌𝗍𝖺 𝖽𝗈𝖾𝗇𝖼̧𝖺 𝗀𝖾𝗇𝖾́𝗍𝗂𝖼𝖺 𝗋𝖺𝗋𝖺 𝖺𝗍𝗂𝗇𝗀𝖾 𝟣 𝖾𝗆 𝖼𝖺𝖽𝖺 𝟣𝟢 𝗆𝗂𝗅 𝗇𝖺𝗌𝖼𝗂𝗆𝖾𝗇𝗍𝗈𝗌 𝗇𝗈 𝗆𝗎𝗇𝖽𝗈, 𝗈 𝗊𝗎𝖾 𝖾𝗆 𝗍𝖾𝗈𝗋𝗂𝖺 𝗌𝗂𝗀𝗇𝗂𝖿𝗂𝖼𝖺 𝗊𝗎𝖾 𝖾𝗆 𝖼𝖺𝖽𝖺 𝖺𝗇𝗈, 𝖾𝗆 𝗆𝖾́𝖽𝗂𝖺, 𝖼𝖾𝗋𝖼𝖺 𝖽𝖾 𝟣𝟦 𝗆𝗂𝗅 𝖼𝗋𝗂𝖺𝗇𝖼̧𝖺𝗌 𝗍𝖾𝗋𝖺̃𝗈 𝖾𝗌𝗍𝖺 𝖽𝗈𝖾𝗇𝖼̧𝖺 𝖾, 𝗉𝗈𝗋𝗍𝖺𝗇𝗍𝗈, 𝗌𝖾𝗋𝖺̃𝗈 𝗍𝖾𝗈𝗋𝗂𝖼𝖺𝗆𝖾𝗇𝗍𝖾 𝖾𝗅𝖾𝗀𝗂́𝗏𝖾𝗂𝗌 𝗉𝖺𝗋𝖺 𝖾𝗌𝗍𝖾 𝗍𝗋𝖺𝗍𝖺𝗆𝖾𝗇𝗍𝗈. 𝖨𝗆𝖺𝗀𝗂𝗇𝖺𝗇𝖽𝗈 𝗊𝗎𝖾 𝖾𝗋𝖺 𝗉𝗈𝗌𝗌𝗂́𝗏𝖾𝗅 𝗍𝗋𝖺𝗍𝖺𝗋 𝗆𝖾𝗍𝖺𝖽𝖾 𝖽𝖾𝗌𝗌𝖾𝗌 𝖻𝖾𝖻𝖾́𝗌 𝖼𝗈𝗆 𝖹𝗈𝗅𝗀𝖾𝗇𝗌𝗆𝖺 𝖾 𝗊𝗎𝖾 𝗈 𝗉𝗋𝖾𝖼̧𝗈 𝖽𝗈 𝗆𝖾𝖽𝗂𝖼𝖺𝗆𝖾𝗇𝗍𝗈 𝖻𝖺𝗂𝗑𝗈𝗎 𝖾𝗇𝗍𝗋𝖾𝗍𝖺𝗇𝗍𝗈 𝟧𝟢% 𝖾𝗆 𝗋𝖾𝗅𝖺𝖼̧𝖺̃𝗈 𝖺𝗈 𝗉𝗋𝖾𝖼̧𝗈 𝖽𝖾 𝟤𝟢𝟤𝟢, 𝖼𝗎𝗌𝗍𝖺𝗇𝖽𝗈 𝖺𝗀𝗈𝗋𝖺 𝟣 𝗆𝗂𝗅𝗁𝖺̃𝗈 𝖽𝖾 𝖾𝗎𝗋𝗈𝗌 (𝗈 𝗊𝗎𝖾 𝗌𝖾𝗋𝗂𝖺 𝖼𝖺𝗋𝗂́𝗌𝗌𝗂𝗆𝗈 𝗆𝖺𝗌, 𝗆𝖾𝗌𝗆𝗈 𝖺𝗌𝗌𝗂𝗆, "𝗌𝗎𝖻𝗌𝗍𝖺𝗇𝖼𝗂𝖺𝗅𝗆𝖾𝗇𝗍𝖾 𝗆𝖺𝗂𝗌 𝖻𝖺𝗂𝗑𝗈" 𝖽𝗈 𝗊𝗎𝖾 𝖺𝗇𝗍𝖾𝗌, 𝖼𝗈𝗆𝗈 𝗃𝗎𝗋𝖺 𝗈 𝖨𝗇𝖿𝖺𝗋𝗆𝖾𝖽), 𝗂𝗌𝗌𝗈 𝗌𝗂𝗀𝗇𝗂𝖿𝗂𝖼𝖺𝗋𝗂𝖺 𝗊𝗎𝖾 𝖺 𝖭𝗈𝗏𝖺𝗋𝗍𝗂𝗌 𝗋𝖾𝖼𝖾𝖻𝖾𝗋𝗂𝖺 𝟩 𝗆𝗂𝗅 𝗆𝗂𝗅𝗁𝗈̃𝖾𝗌 𝖽𝖾 𝖾𝗎𝗋𝗈𝗌 𝗇𝗎𝗆 𝗎́𝗇𝗂𝖼𝗈 𝖺𝗇𝗈 𝗉𝖾𝗅𝖺 𝗏𝖾𝗇𝖽𝖺 𝖽𝖾𝗌𝗌𝖾 𝖿𝖺́𝗋𝗆𝖺𝖼𝗈, 𝗎𝗆 𝗏𝖺𝗅𝗈𝗋 𝗆𝗎𝗂𝗍𝗈 𝖺𝖼𝗂𝗆𝖺 𝖽𝖺𝗌 "𝖼𝖾𝗇𝗍𝖾𝗇𝖺𝗌 𝖽𝖾 𝗆𝗂𝗅𝗁𝗈̃𝖾𝗌 𝖽𝖾 𝖽𝗈́𝗅𝖺𝗋𝖾𝗌" 𝗂𝗇𝗏𝖾𝗌𝗍𝗂𝖽𝗈𝗌 𝗇𝗈 𝗌𝖾𝗎 𝖽𝖾𝗌𝖾𝗇𝗏𝗈𝗅𝗏𝗂𝗆𝖾𝗇𝗍𝗈.
𝖬𝖾𝗌𝗆𝗈 𝗌𝖾 𝗈 𝗍𝗋𝖺𝗍𝖺𝗆𝖾𝗇𝗍𝗈 𝗌𝗈́ 𝖿𝗈𝗌𝗌𝖾 𝖽𝖺𝖽𝗈 𝖺 𝗆𝗂𝗅 𝖼𝗋𝗂𝖺𝗇𝖼̧𝖺𝗌, 𝗈𝗌 𝗅𝗎𝖼𝗋𝗈𝗌 𝗃𝖺́ 𝗌𝖾𝗋𝗂𝖺𝗆 𝗌𝗎𝖻𝗌𝗍𝖺𝗇𝖼𝗂𝖺𝗂𝗌. 𝖢𝗈𝗆𝗈 𝖾𝗅𝖾 𝖾́ 𝖼𝗈𝗆𝖾𝗋𝖼𝗂𝖺𝗅𝗂𝗓𝖺𝖽𝗈 𝖽𝖾𝗌𝖽𝖾 𝟤𝟢𝟣𝟫, 𝖺𝖽𝗂𝗏𝗂𝗇𝗁𝗈 𝗎𝗆𝖺 𝖿𝖺𝗍𝗎𝗋𝖺𝖼̧𝖺̃𝗈 𝖼𝗈𝗅𝗈𝗌𝗌𝖺𝗅 𝗉𝖺𝗌𝗌𝖺𝖽𝖺 𝗉𝖾𝗅𝖺 𝖭𝗈𝗏𝖺𝗋𝗍𝗂𝗌 𝖾𝗆 𝗆𝗎́𝗅𝗍𝗂𝗉𝗅𝗈𝗌 𝗉𝖺𝗂́𝗌𝖾𝗌, 𝗂𝗇𝖼𝗅𝗎𝗂𝗇𝖽𝗈 𝖯𝗈𝗋𝗍𝗎𝗀𝖺𝗅.
𝖮 𝗊𝗎𝖾 𝖺𝖼𝖺𝖻𝖾𝗂 𝖽𝖾 𝖾𝗌𝖼𝗋𝖾𝗏𝖾𝗋 𝖾́ 𝖾𝗌𝗉𝖾𝖼𝗎𝗅𝖺𝗍𝗂𝗏𝗈 𝖾 𝗉𝗈𝖽𝖾 𝖾𝗌𝗍𝖺𝗋 𝗍𝗈𝗍𝖺𝗅𝗆𝖾𝗇𝗍𝖾 𝖾𝗋𝗋𝖺𝖽𝗈 - 𝗆𝖺𝗌 𝖾𝗌𝗌𝖾 𝖾𝗋𝗋𝗈 𝖺𝖽𝗏𝖾́𝗆 𝖽𝖺 𝗍𝗈𝗍𝖺𝗅 𝗈𝗉𝖺𝖼𝗂𝖽𝖺𝖽𝖾 𝖼𝗈𝗆 𝗊𝗎𝖾 𝗌𝖾 𝖼𝗈𝗆𝖾𝗋𝖼𝗂𝖺𝗅𝗂𝗓𝖺𝗆 𝖾𝗌𝗍𝖾 𝖾 𝗈𝗎𝗍𝗋𝗈𝗌 𝗍𝗂𝗉𝗈𝗌 𝖽𝖾 𝗆𝖾𝖽𝗂𝖼𝖺𝗆𝖾𝗇𝗍𝗈𝗌 𝖾 𝖽𝖺 𝖺𝖼𝖾𝗂𝗍𝖺𝖼̧𝖺̃𝗈 𝗉𝖾𝗅𝗈𝗌 𝖤𝗌𝗍𝖺𝖽𝗈𝗌 𝖾 𝗉𝖾𝗅𝗈𝗌 𝗈𝗋𝗀𝖺𝗇𝗂𝗌𝗆𝗈𝗌 𝗋𝖾𝗀𝗎𝗅𝖺𝖽𝗈𝗋𝖾𝗌 𝖽𝖾 𝖼𝗅𝖺́𝗎𝗌𝗎𝗅𝖺𝗌 𝖽𝖾 𝖼𝗈𝗇𝖿𝗂𝖽𝖾𝗇𝖼𝗂𝖺𝗅𝗂𝖽𝖺𝖽𝖾, 𝖼𝗈𝗆𝗈 𝖺 𝗊𝗎𝖾 𝗈 𝖨𝗇𝖿𝖺𝗋𝗆𝖾𝖽 𝖼𝗂𝗍𝖺.
𝖤𝗌𝗌𝖾 𝗌𝖾𝖼𝗋𝖾𝗍𝗂𝗌𝗆𝗈 𝗂𝗆𝗉𝖾𝖽𝖾 𝗈 𝖾𝗌𝖼𝗋𝗎𝗍𝗂́𝗇𝗂𝗈 𝗉𝗎́𝖻𝗅𝗂𝖼𝗈 𝖽𝖺𝗌 𝖽𝖾𝗌𝗉𝖾𝗌𝖺𝗌, 𝖼𝖺𝖽𝖺 𝗏𝖾𝗓 𝗆𝖺𝗂𝗌 𝖾𝗅𝖾𝗏𝖺𝖽𝖺𝗌, 𝖼𝗈𝗆 𝗆𝖾𝖽𝗂𝖼𝖺𝗆𝖾𝗇𝗍𝗈𝗌, 𝗊𝗎𝖾 𝖺𝗍𝗂𝗇𝗀𝖾𝗆 𝖾𝗆 𝗍𝗈𝖽𝗈 𝗈 𝗆𝗎𝗇𝖽𝗈 𝗊𝗎𝖺𝗇𝗍𝗂𝖺𝗌 𝗏𝖾𝗋𝖽𝖺𝖽𝖾𝗂𝗋𝖺𝗆𝖾𝗇𝗍𝖾 𝖺𝗌𝗍𝗋𝗈𝗇𝗈́𝗆𝗂𝖼𝖺𝗌, 𝖽𝖾 𝖾𝗑𝗉𝗅𝗂𝖼𝖺𝖼̧𝖺̃𝗈 𝖽𝗂𝖿𝗂́𝖼𝗂𝗅, 𝗌𝖾𝗇𝖽𝗈 𝗊𝗎𝖾 𝖾𝗌𝗌𝖾 𝖽𝗂𝗇𝗁𝖾𝗂𝗋𝗈, 𝗇𝗈 𝖼𝖺𝗌𝗈 𝖽𝖾 𝖯𝗈𝗋𝗍𝗎𝗀𝖺𝗅 𝖾 𝖽𝖾 𝗆𝗎𝗂𝗍𝗈𝗌 𝗈𝗎𝗍𝗋𝗈𝗌 𝗉𝖺𝗂́𝗌𝖾𝗌, 𝖾́ 𝗉𝖺𝗀𝗈, 𝗇𝖺 𝗌𝗎𝖺 𝗆𝖺𝗂𝗈𝗋 𝖿𝖺𝗍𝗂𝖺, 𝗉𝖾𝗅𝗈𝗌 𝖼𝗈𝗇𝗍𝗋𝗂𝖻𝗎𝗂𝗇𝗍𝖾𝗌.
𝖯𝗈𝗋 𝗈𝗎𝗍𝗋𝗈 𝗅𝖺𝖽𝗈, 𝗈 𝗏𝖺𝗅𝗈𝗋 𝖽𝗈 𝗂𝗇𝗏𝖾𝗌𝗍𝗂𝗆𝖾𝗇𝗍𝗈 𝖿𝖾𝗂𝗍𝗈 𝗉𝖾𝗅𝖺𝗌 𝖾𝗆𝗉𝗋𝖾𝗌𝖺𝗌 𝖿𝖺𝗋𝗆𝖺𝖼𝖾̂𝗎𝗍𝗂𝖼𝖺𝗌 𝖾𝗆 𝗇𝗈𝗏𝖺𝗌 𝖽𝖾𝗌𝖼𝗈𝖻𝖾𝗋𝗍𝖺𝗌 𝗍𝖺𝗆𝖻𝖾́𝗆 𝖾́ 𝗌𝖾𝖼𝗋𝖾𝗍𝗈 𝖾 𝗇𝗂𝗇𝗀𝗎𝖾́𝗆 𝗈 𝖾𝗌𝖼𝗋𝗎𝗍𝗂𝗇𝖺, 𝗈 𝗊𝗎𝖾 𝗅𝖾𝗏𝖺 𝖺 𝗊𝗎𝖾 𝖾𝗅𝖺𝗌 𝗉𝗈𝗌𝗌𝖺𝗆 𝖺𝗅𝖾𝗀𝖺𝗋 𝗌𝖾𝗋𝖾𝗆 𝗃𝗎𝗌𝗍𝗈𝗌 𝗈𝗌 𝗉𝗋𝖾𝖼̧𝗈𝗌 𝗉𝗋𝗈𝗂𝖻𝗂𝗍𝗂𝗏𝗈𝗌 𝗊𝗎𝖾 𝗉𝗋𝖺𝗍𝗂𝖼𝖺𝗆 - 𝖾, 𝖼𝗈𝗆𝗈 𝖾𝗌𝗍𝖺̃𝗈 𝗏𝗂𝖽𝖺𝗌 𝗁𝗎𝗆𝖺𝗇𝖺𝗌 𝖾𝗆 𝗃𝗈𝗀𝗈, 𝗉𝗈𝗎𝖼𝖺 𝗀𝖾𝗇𝗍𝖾 𝗍𝖾𝗆 𝗆𝗈𝗋𝖺𝗅 𝗉𝖺𝗋𝖺 𝗊𝗎𝖾𝗌𝗍𝗂𝗈𝗇𝖺𝗋 𝖾𝗌𝗌𝖺 𝗉𝗋𝖺́𝗍𝗂𝖼𝖺.
𝖢𝗈𝗆 𝗈𝗌 𝖽𝖺𝖽𝗈𝗌 𝗊𝗎𝖾 𝖼𝗈𝗇𝗁𝖾𝖼𝖾𝗆𝗈𝗌, 𝖾 𝖼𝗈𝗆 𝗈𝗌 𝗋𝖺𝖼𝗂𝗈𝖼𝗂́𝗇𝗂𝗈𝗌 𝗊𝗎𝖾 𝖾𝗅𝖾𝗌 𝗇𝗈𝗌 𝗉𝖾𝗋𝗆𝗂𝗍𝖾𝗆, 𝗍𝖾𝗆𝗈𝗌 𝖽𝗂𝗋𝖾𝗂𝗍𝗈 𝖺 𝖽𝖾𝗌𝖼𝗈𝗇𝖿𝗂𝖺𝗋 𝖽𝖺 𝖾𝗑𝗂𝗌𝗍𝖾̂𝗇𝖼𝗂𝖺 𝖽𝖾 𝗅𝗎𝖼𝗋𝗈𝗌 𝖺𝖻𝗎𝗌𝗂𝗏𝗈𝗌 𝗇𝗈 𝖼𝖺𝗌𝗈 𝖽𝗈 𝖹𝗈𝗅𝗀𝖾𝗇𝗌𝗆𝖺 𝖾 𝗅𝖾𝗀𝗂𝗍𝗂𝗆𝗂𝖽𝖺𝖽𝖾 𝗉𝖺𝗋𝖺 𝖺𝖿𝗂𝗋𝗆𝖺𝗋 𝗊𝗎𝖾, 𝗆𝖺𝗂𝗈𝗋 𝖾𝗌𝖼𝖺̂𝗇𝖽𝖺𝗅𝗈 𝗊𝗎𝖾 𝖺 𝖾𝗏𝖾𝗇𝗍𝗎𝖺𝗅 𝖼𝗎𝗇𝗁𝖺 𝗊𝗎𝖾 𝗍𝖾𝗋𝖺́ 𝗅𝖾𝗏𝖺𝖽𝗈 𝖺̀ 𝗆𝗂𝗇𝗂𝗌𝗍𝗋𝖺𝖼̧𝖺̃𝗈 𝖽𝖾 𝗎𝗆 𝗆𝖾𝖽𝗂𝖼𝖺𝗆𝖾𝗇𝗍𝗈 𝗊𝗎𝖾 𝖼𝗎𝗌𝗍𝖺 𝟤 𝗆𝗂𝗅𝗁𝗈̃𝖾𝗌 𝖽𝖾 𝖾𝗎𝗋𝗈𝗌 𝖺 𝖽𝗎𝖺𝗌 𝖻𝖾𝖻𝖾́𝗌, 𝖾́ 𝗈 𝗉𝗋𝖾𝖼̧𝗈 𝗈𝖻𝗌𝖼𝖾𝗇𝗈 𝖽𝖾𝗌𝗌𝖾 𝖿𝖺́𝗋𝗆𝖺𝖼𝗈 𝖾 𝗈 𝖼𝗈𝗇𝗍𝗋𝖺𝗍𝗈 𝗌𝖾𝖼𝗋𝖾𝗍𝗈 𝖽𝗈 𝖨𝗇𝖿𝖺𝗋𝗆𝖾𝖽 𝗉𝖺𝗋𝖺 𝖺 𝗌𝗎𝖺 𝖺𝗊𝗎𝗂𝗌𝗂𝖼̧𝖺̃𝗈 𝖾𝗆 𝖯𝗈𝗋𝗍𝗎𝗀𝖺𝗅, 𝗊𝗎𝖾 𝗈𝖿𝗂𝖼𝗂𝖺𝗅𝗂𝗓𝖺 𝖾𝗌𝗌𝖺 𝗈𝖻𝗌𝖼𝖾𝗇𝗂𝖽𝖺𝖽𝖾.
𝖲𝖾 𝖾𝗌𝗍𝖺 𝖺𝖿𝗂𝗋𝗆𝖺𝖼̧𝖺̃𝗈 𝖿𝗈𝗋 𝗂𝗇𝗃𝗎𝗌𝗍𝖺, 𝖾𝗇𝗍𝖺̃𝗈 𝗉𝗋𝗈𝗏𝖾𝗆-𝗇𝗈, 𝖼𝗅𝖺𝗋𝖺𝗆𝖾𝗇𝗍𝖾, 𝖼𝗈𝗆 𝗍𝗈𝖽𝖺𝗌 𝖺𝗌 𝖼𝗈𝗇𝗍𝗂𝗇𝗁𝖺𝗌 𝖺̀ 𝗆𝗈𝗌𝗍𝗋𝖺, 𝗌𝖾 𝖿𝖺𝗓 𝖿𝖺𝗏𝗈𝗋.
𝖠 𝖨𝗇𝗂𝖼𝗂𝖺𝗍𝗂𝗏𝖺 𝖫𝗂𝖻𝖾𝗋𝖺𝗅, 𝖺𝗈 𝗍𝖾𝗇𝗍𝖺𝗋 𝗅𝖾𝗀𝗂𝗍𝗂𝗆𝖺𝗆𝖾𝗇𝗍𝖾 𝖺𝗉𝗋𝗈𝗏𝖾𝗂𝗍𝖺𝗋 𝗈 𝖾𝗌𝖼𝖺̂𝗇𝖽𝖺𝗅𝗈 𝗉𝖺𝗋𝖺 𝗋𝖾𝗍𝗂𝗋𝖺𝗋 𝖽𝗂𝗏𝗂𝖽𝖾𝗇𝖽𝗈𝗌 𝗉𝗈𝗅𝗂́𝗍𝗂𝖼𝗈𝗌, 𝖺𝗇𝗎𝗇𝖼𝗂𝗈𝗎 𝗊𝗎𝖾 𝗊𝗎𝖾𝗋 𝖿𝖺𝗓𝖾𝗋 𝗎𝗆𝖺 𝖺𝗎𝖽𝗂𝖼̧𝖺̃𝗈 𝗉𝖺𝗋𝗅𝖺𝗆𝖾𝗇𝗍𝖺𝗋 𝗌𝗈𝖻𝗋𝖾 𝗈 𝖼𝖺𝗌𝗈 𝖺̀ 𝗆𝗂𝗇𝗂𝗌𝗍𝗋𝖺 𝖽𝖺 𝖲𝖺𝗎́𝖽𝖾 𝖽𝖺 𝖾́𝗉𝗈𝖼𝖺, 𝖬𝖺𝗋𝗍𝖺 𝖳𝖾𝗆𝗂𝖽𝗈, 𝖺𝗈 𝗌𝖾𝖼𝗋𝖾𝗍𝖺́𝗋𝗂𝗈 𝖽𝖾 𝖤𝗌𝗍𝖺𝖽𝗈 𝖽𝖺 𝖺𝗅𝗍𝗎𝗋𝖺, 𝖫𝖺𝖼𝖾𝗋𝖽𝖺 𝖲𝖺𝗅𝖾𝗌, 𝖾 𝖺𝗈 𝖿𝗂𝗅𝗁𝗈 𝖽𝗈 𝖯𝗋𝖾𝗌𝗂𝖽𝖾𝗇𝗍𝖾 𝖽𝖺 𝖱𝖾𝗉𝗎́𝖻𝗅𝗂𝖼𝖺, 𝖭𝗎𝗇𝗈 𝖱𝖾𝖻𝖾𝗅𝗈 𝖽𝖾 𝖲𝗈𝗎𝗌𝖺, 𝗈 𝗌𝗎𝗉𝗈𝗌𝗍𝗈 "𝗂𝗇𝖿𝗅𝗎𝖾𝗇𝖼𝗂𝖺𝖽𝗈𝗋" 𝗉𝖺𝗋𝖺 𝖺 𝖺𝗅𝖾𝗀𝖺𝖽𝖺 "𝖼𝗎𝗇𝗁𝖺". 𝖯𝖾𝗅𝗈 𝗆𝖾𝗇𝗈𝗌 𝖺𝗍𝖾́ 𝖺𝗀𝗈𝗋𝖺 𝖺 𝖭𝗈𝗏𝖺𝗋𝗍𝗂𝗌 𝖾 𝗈 𝖨𝗇𝖿𝖺𝗋𝗆𝖾𝖽 𝖿𝗂𝖼𝖺𝗋𝖺𝗆 𝖽𝖾 𝖿𝗈𝗋𝖺 𝖽𝖾𝗌𝗌𝖺 𝗂𝗇𝗍𝖾𝗇𝖼̧𝖺̃𝗈 𝖽𝖾 𝗂𝗇𝗊𝗎𝗂𝗋𝗂𝖼̧𝖺̃𝗈 𝖺𝗇𝗎𝗇𝖼𝗂𝖺𝖽𝖺 𝗉𝗈𝗋 𝖱𝗎𝗂 𝖱𝗈𝖼𝗁𝖺...
...𝖠𝗍𝖾́ 𝗂𝗆𝖺𝗀𝗂𝗇𝗈 𝗈 𝖻𝗋𝖺𝖽𝗈 𝗉𝗈𝗋 𝖺𝗊𝗎𝖾𝗅𝖺𝗌 𝖻𝖺𝗇𝖽𝖺𝗌: "𝖫𝗈𝗇𝗀𝖺 𝗏𝗂𝖽𝖺 𝖺̀ 𝗂𝗇𝗂𝖼𝗂𝖺𝗍𝗂𝗏𝖺 𝗉𝗋𝗂𝗏𝖺𝖽𝖺!"
* Jornalista
IN "DIÁRIO DE NOTÍCIAS" - 13/12/23.
Sem comentários:
Enviar um comentário